Search research articles
Contact Us
Filters
Showing results (501-510 of 520) with videos related to
Page
of 52
Sort By:
Data in Brief
|
August 26, 2015
Altering adsorbed proteins or cellular gene expression in bone-metastatic cancer cells affects PTHrP and Gli2 without altering cell growth
Jonathan M Page, Alyssa R Merkel, Nazanin S Ruppender, et al.
Journal of Neuro-Oncology
|
December 12, 2007
The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression
Michael J Fisher, Sandip Basu, Eva Dombi, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 21, 2013
FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity
Babak Saboury, Ali Salavati, Alex Brothers, et al.
Hellenic Journal of Nuclear Medicine
|
July 16, 2011
Detection and global quantification of cardiovascular molecular calcification by fluoro18-fluoride positron emission tomography/computed tomography--a novel concept
Mohsen Beheshti, Babak Saboury, Nehal N Mehta, et al.
Clinical Nuclear Medicine
|
February 13, 2024
Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma
Yoga S Narwadkar, Rahul V Parghane, Sudeep Sahu, et al.
Nuclear Medicine Communications
|
June 10, 2011
'Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs
Sandip Basu, Amit Abhyankar, Purushottam Kand, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
March 22, 2021
On the Separation of Yttrium-90 from High-Level Liquid Waste: Purification to Clinical-Grade Radiochemical Precursor, Clinical Translation in Formulation of <sup>90</sup>Y-DOTATATE Patient Dose
Arpit Mitra, Avik Chakraborty, Sujay Gaikwad, et al.
Hellenic Journal of Nuclear Medicine
|
February 14, 2015
Effects of age and cardiovascular risk factors on (18)F-FDG PET/CT quantification of atherosclerosis in the aorta and peripheral arteries
Ahmed K Pasha, Mateen Moghbel, Babak Saboury, et al.
Nuclear Medicine Communications
|
November 12, 2015
Quantification of aging effects upon global knee inflammation by 18F-FDG-PET
Babak Saboury, Molly A Parsons, Mateen Moghbel, et al.
Clinical Nuclear Medicine
|
May 31, 2014
FDG PET for diagnosing infection in hip and knee prostheses: prospective study in 221 prostheses and subgroup comparison with combined (111)In-labeled leukocyte/(99m)Tc-sulfur colloid bone marrow imaging in 88 prostheses
Sandip Basu, Thomas C Kwee, Babak Saboury, et al.
Page
of 52
Search research articles
Search
Showing results (501-510 of 520) with videos related to
Sort By:
Page
of 52
Data in Brief
|
August 26, 2015
Altering adsorbed proteins or cellular gene expression in bone-metastatic cancer cells affects PTHrP and Gli2 without altering cell growth
Jonathan M Page, Alyssa R Merkel, Nazanin S Ruppender, et al.
Journal of Neuro-Oncology
|
December 12, 2007
The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression
Michael J Fisher, Sandip Basu, Eva Dombi, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 21, 2013
FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity
Babak Saboury, Ali Salavati, Alex Brothers, et al.
Hellenic Journal of Nuclear Medicine
|
July 16, 2011
Detection and global quantification of cardiovascular molecular calcification by fluoro18-fluoride positron emission tomography/computed tomography--a novel concept
Mohsen Beheshti, Babak Saboury, Nehal N Mehta, et al.
Clinical Nuclear Medicine
|
February 13, 2024
Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma
Yoga S Narwadkar, Rahul V Parghane, Sudeep Sahu, et al.
Nuclear Medicine Communications
|
June 10, 2011
'Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs
Sandip Basu, Amit Abhyankar, Purushottam Kand, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
March 22, 2021
On the Separation of Yttrium-90 from High-Level Liquid Waste: Purification to Clinical-Grade Radiochemical Precursor, Clinical Translation in Formulation of <sup>90</sup>Y-DOTATATE Patient Dose
Arpit Mitra, Avik Chakraborty, Sujay Gaikwad, et al.
Hellenic Journal of Nuclear Medicine
|
February 14, 2015
Effects of age and cardiovascular risk factors on (18)F-FDG PET/CT quantification of atherosclerosis in the aorta and peripheral arteries
Ahmed K Pasha, Mateen Moghbel, Babak Saboury, et al.
Nuclear Medicine Communications
|
November 12, 2015
Quantification of aging effects upon global knee inflammation by 18F-FDG-PET
Babak Saboury, Molly A Parsons, Mateen Moghbel, et al.
Clinical Nuclear Medicine
|
May 31, 2014
FDG PET for diagnosing infection in hip and knee prostheses: prospective study in 221 prostheses and subgroup comparison with combined (111)In-labeled leukocyte/(99m)Tc-sulfur colloid bone marrow imaging in 88 prostheses
Sandip Basu, Thomas C Kwee, Babak Saboury, et al.
Page
of 52